KLF4 was upregulated in osteosarcoma and primary breast ductal carcinoma [10, 11], but downregulated in lung cancer, gastric cancer, hepatoma, prostate cancer, and renal cell carcinoma suggesting its tumor suppressor role [12–16]. Here, KLF4 is linked to renal cell carcinoma.